Work

Initial results from a phase 2 study of cladribine, cytarabine, and granulocyte-colony stimulating factor with gemtuzumab ozogamicin (CLAG-GO) for the treatment of patients with relapsed/refractory acute myeloid leukemia

Year: 2025

Type: conference-abstract

Source: Blood

DOI: 10.1182/blood-2025-999

Authors: David Chen, Maria Baer, Sandrine Niyongere, Ashkan Emadi, Vivek Shastri, Jatinder Lamba, Michael Loken, Larissa Sanglard, Rena Lapidus, Soren Bentzen, Vu Duong

Institutions: University of Maryland, Baltimore, University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, West Virginia University, University of Florida

Language: English

Topic: Acute Myeloid Leukemia Research

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4417015666

Cites:

Cited by:

Related to: